Status:
COMPLETED
QST-Pupillometry in Sickle Cell Disease Patients
Lead Sponsor:
Julia Finkel
Conditions:
SCD With Severe Phenotype (HbSS, HbSβ0 Thalassemia, HbSOARab)
Eligibility:
All Genders
13-30 years
Brief Summary
There has been little progress for effective treatment of pain in sickle cell disease (SCD) patients. Many organizations have recognized that understanding the causes and reducing the burden of pain i...
Eligibility Criteria
Inclusion
- SCD with severe phenotype (HbSS, HbSbeta0 thalassemia, HbSOArab)
- Relatives of SCD patients who do not have sickle cell trait or SCD; healthy controls
Exclusion
- Completed overt clinical stroke or transient ischemic attack;
- Known severe vasculopathy or Moyamoya disease on brain MRA (Magnetic Resonance Angiography).
- history of having consumed alcohol within the last 12 hours prior to testing.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2018
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT02242058
Start Date
August 1 2013
End Date
November 1 2018
Last Update
January 21 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's National Health System
Washington D.C., District of Columbia, United States, 20010
2
Children's National Medical Center
Washington D.C., District of Columbia, United States, 20010